VERA - Vera Therapeutics extends gains to reach a two-month high

Vera Therapeutics (VERA +25.5%) closed higher for the third straight session recording the best intraday performance in over two months to reach the highest level since mid-September. The clinical-stage biotech has more than doubled in value since its IPO in mid-May. However, the shares experienced volatility along the way. Two months ago, Vera (NASDAQ:VERA) fell for five consecutive sessions recording the biggest intraday loss in mid-September. All three analysts covering the stock have issued Bullish views. San Francisco, California-based company is advancing its leading candidate atacicept for immunoglobulin A nephropathy (IgAN). Last week, Vera (VERA) announced clinical results for atacicept from a Phase 2a trial involving patients with IgAN. The data indicated a dose-dependent effect of the experimental therapy on serum galactose-deficient IgA1 (Gd-IgA1), a key biomarker in the disease.

For further details see:

Vera Therapeutics extends gains to reach a two-month high